Diabetes mellitus: pathophysiological changes and therap

Biermasz, N.

Bolanowski, M.

Fleseriu, M.

Gordon, M.B.

Greenman, Y.

Haviv, A.

Kennedy, L.

Labadzhyan, A.

Ludlam, W.

Molitch, M.

Nachtigall, L.B.

Patou, G.

Samson, S.L.

Strasburger, C.J.

Leiden University Scholary Publications

Oral octreotide capsules for the treatment of acromegaly: comparisonof 2 phase 3 trial results (June, 10.1007/s11102-021-01163-2, 2021)Labadzhyan, A.; Nachtigall, L.B.; Fleseriu, M.; Gordon, M.B.; Molitch, M.; Kennedy, L.; ... ;Strasburger, C.J.CitationLabadzhyan, A., Nachtigall, L. B., Fleseriu, M., Gordon, M. B., Molitch, M., Kennedy, L., …Strasburger, C. J. (2021). Oral octreotide capsules for the treatment of acromegaly:comparison of 2 phase 3 trial results (June, 10.1007/s11102-021-01163-2, 2021). Pituitary,24(6), 954-954. doi:10.1007/s11102-021-01177-w Version: Publisher's VersionLicense: Creative Commons CC BY 4.0 licenseDownloaded from: https://hdl.handle.net/1887/3237853 Note: To cite this publication please use the final published version (if applicable).Vol:.(1234567890)Pituitary (2021) 24:954https://doi.org/10.1007/s11102-021-01177-w1 3CORRECTIONCorrection to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial resultsArtak Labadzhyan1 · L B Nachtigall2 · M Fleseriu3  · M B Gordon4 · M Molitch5 · L Kennedy6 · S L Samson7  · Y Greenman8  · N Biermasz9  · M Bolanowski10  · A Haviv11 · W Ludlam1 · G Patou11 · C J Strasburger12 Published online: 4 August 2021 © The Author(s) 2021Correction to:  Pituitary  https:// doi. org/ 10. 1007/ s11102- 021- 01163-2The article ‘Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results’, written by Artak Labadzhyan, L B Nachtigall, M Fleseriu, M B Gor-don, M Molitch, L Kennedy, S L Samson, Y Greenman, N Biermasz, M Bolanowski, A Haviv, W Ludlam, G Patou and C J Strasburger was originally published electronically on the publisher’s internet portal on 25 June 2021 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 15 July 2021 to © The Author(s) 2021 and the article is forthwith distrib-uted under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribu-tion and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4.0.The original article has been corrected.Open Access This article is licensed under a Creative Commons Attri-bution 4.0 International License, which permits use, sharing, adapta-tion, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.The original article can be found online at https:// doi. org/ 10. 1007/ s11102- 021- 01163-2. * Artak Labadzhyan  Artak.Labadzhyan@cshs.org1 Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA2 MGH Neuroendocrine and Pituitary Center, Chestnut Hill, MA, USA3 Pituitary Center, Oregon Health & Sciences University, Portland, OR, USA4 Allegheny Neuroendocrinology Center, Allegheny General Hospital, Pittsburgh, PA, USA5 Northwestern University, Chicago, IL, USA6 Cleveland Clinic Foundation, Cleveland, OH, USA7 Mayo Clinic, Jacksonville, FL, USA8 Sourasky Medical Center and Tel Aviv University, Tel Aviv, Israel9 Leiden University Medical Center, Leiden, The Netherlands10 Wroclaw Medical University, Wroclaw, Poland11 Chiasma, Inc., Needham, MA, USA12 Charite Universitatsmedizin, Berlin, Germany

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results (June, 10.1007/s11102-021-01163-2, 2021)

https://scholarlypublications.universiteitleiden.nl/access/item%3A3308712/download

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results (June, 10.1007/s11102-021-01163-2, 2021)

Abstract

Similar works

Full text

Available Versions

Leiden University Scholary Publications